These studies indicate that CLRs may also utilize the classical SYK/CARD9 pathway to induce the expansion of CD8+ T cells in the tumor microenvironment in bladder cancer and thus influence ICB therapy efficacy. This evidence concerns the gene CD8A and urinary bladder cancer.